

**CHEMU PHARMA LABORATORIES LIMITED**

EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001  
 TEL: 91-22-22078384, 22078382 • FAX: 91-22-22074294  
 CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K  
 www.thechemopharmalaboratoriesltd.com  
 EMAIL: chemopharmalab@gmail.com

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2014**

(Rs in '000)

Sr. No.	Particulars	Quarter Ended			Cumulative Half Year Ended		Year Ended
		30th Sept 2014	30th June 2014	30th Sept 2013	30th Sept 2014	30th Sept 2013	31st March 2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
	(a) Net Sales/ Income from Operations (Net of excise)	-	-	-	-	-	-
	(b) Other Operating Income	1,134	1,102	1,155	2,236	1,787	4,388
	<b>Total Income from operations (net)</b>	<b>1,134</b>	<b>1,102</b>	<b>1,155</b>	<b>2,236</b>	<b>1,787</b>	<b>4,388</b>
2	<b>Expenses</b>						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchases of Stock-in-trade	-	-	-	-	-	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefits expenses	48	48	41	96	81	162
	(e) Depreciation and amortisation expense	9	9	11	18	23	46
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	269	42	98	311	157	255
	i) Professional Charges	63	-	33	63	297	841
	ii) Share Registry Expenses	26	18	-	44	-	68
	<b>Total Expenses</b>	<b>415</b>	<b>116</b>	<b>183</b>	<b>532</b>	<b>558</b>	<b>1,372</b>
3	<b>Profit / Loss from Operation before other Income, Finance cost and exceptional items (1-2)</b>	<b>719</b>	<b>986</b>	<b>972</b>	<b>1,705</b>	<b>1,229</b>	<b>3,016</b>
4	<b>Other Income</b>	-	-	-	-	-	-
5	<b>Profit / Loss from ordinary activities before Finance cost and exceptional items (3+4)</b>	<b>719</b>	<b>986</b>	<b>972</b>	<b>1,705</b>	<b>1,229</b>	<b>3,016</b>
6	<b>Finance Costs</b>	-	-	-	-	-	-
7	<b>Profit / Loss from ordinary activities after Finance cost but before exceptional items (5+6)</b>	<b>719</b>	<b>986</b>	<b>972</b>	<b>1,705</b>	<b>1,229</b>	<b>3,016</b>
8	<b>Exceptional Items</b>	-	-	-	-	-	-
9	<b>Net Profit/(Loss) from ordinary activities before tax (7+8)</b>	<b>719</b>	<b>986</b>	<b>972</b>	<b>1,705</b>	<b>1,229</b>	<b>3,016</b>
10	<b>Tax expenses</b>	-	-	-	-	-	605
11	<b>Net Profit/(Loss) from ordinary activities after tax (9+10)</b>	<b>719</b>	<b>986</b>	<b>972</b>	<b>1,705</b>	<b>1,229</b>	<b>2,411</b>
12	<b>Extra ordinary items (net of tax expenses Rs. )</b>	-	-	-	-	-	-
13	<b>Net Profit/ (Loss) for the period (11+12)</b>	<b>719</b>	<b>986</b>	<b>972</b>	<b>1,705</b>	<b>1,229</b>	<b>2,411</b>
14	<b>Share of Profit/ (Loss) of associate*</b>	-	-	-	-	-	-
15	<b>Minority interest *</b>	-	-	-	-	-	-
16	<b>Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*</b>	<b>719</b>	<b>986</b>	<b>972</b>	<b>1,705</b>	<b>1,229</b>	<b>2,411</b>
17	<b>Paid-up equity share Capital (face value of Rs. 10/- each)</b>	<b>15,000</b>	<b>15,000</b>	<b>15,000</b>	<b>15,000</b>	<b>15,000</b>	<b>15,000</b>
18	<b>Reserves excluding revaluation reserve as per balance sheet of previous accounting year</b>	<b>35,210</b>	<b>33,506</b>	<b>32,322</b>	<b>35,210</b>	<b>32,322</b>	<b>33,506</b>
19	<b>i) Earning per share (before extraordinary items) of Rs. 10/- each (not annualised) :</b>						
	(a) Basic	0.48	0.66	0.65	1.14	0.82	1.61
	(b) Diluted						
19	<b>ii) Earning per share (after extraordinary items) of Rs. 10/- each (not annualised) :</b>						
	(a) Basic	0.48	0.66	0.65	1.14	0.82	1.61
	(b) Diluted						



**CHEMO PHARMA LABORATORIES LIMITED**

- EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001
- TEL: 91-22-22078381, 22078382 • FAX: 91-22-22074294
- CIN No.: L99999MH1942PLC003856 • PAN No.: AAACC2056K
- www.thechemopharmalaboratoriesltd.com
- EMAIL: chemopharmalab@gmail.com

<b>A PARTICULARS OF SHAREHOLDING</b>						
<b>1</b>	<b>Public Shareholding</b>					
	- Number of shares	1,081,719	1,081,719	1,081,719	1,081,719	1,081,719
	- Percentage of shareholding	72.11	72.11	72.11	72.11	72.11
<b>19</b>	<b>Promoters and Promoter Group shareholding**</b>					
	<b>a) Pledged/Encumbered</b>					
	- Number of shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of company)	NIL	NIL	NIL	NIL	NIL
	<b>b) Non-Encumbered</b>					
	- Number of shares	418,281	418,281	418,281	418,281	418,281
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of company)	27.89	27.89	27.89	27.89	27.89

**Note :**

1. The above unaudited financial results have been taken on record by Audit Committee in their meeting on 21.10.2014 and also approved by the Board in their meeting held on 21.10.2014
2. Separate segment reporting is not applicable to the company.



Place : Mumbai  
Date : 21st October, 2014

By Order of the Board  
For Chemo - Pharma Laboratories Limited

*(Signature)*  
Director

**CHEMO PHARMA LABORATORIES LIMITED**

- EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001
- TEL: 91-22-22078381, 22078382 • FAX: 91-22-22074294
- CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
- www.thechemopharmalaboratoriesltd.com
- EMAIL: chemopharmalab@gmail.com

**STANDALONE STATEMENT OF ASSETS & LIABILITIES  
AS PER CLAUSE 41 OF THE LISTING AGREEMENT**

(Rupees in thousands)

Sr. No.	PARTICULARS	As at 30.09.2014 RUPEES	As at 31.03.2014 RUPEES
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>SHAREHOLDERS' FUNDS</b>		
	(a) Share Capital	15,000	15,000
	(b) Reserves and Surplus	+	
		35,210	33,505
	<b>Sub Total - Shareholders' Funds</b>	<b>50,210</b>	<b>48,505</b>
<b>2</b>	<b>NON CURRENT LIABILITIES</b>		
	(a) Other Long Term Liabilities	1,197	1,197
	<b>Sub Total - Non - Current Liabilities</b>	<b>1,197</b>	<b>1,197</b>
<b>3</b>	<b>CURRENT LIABILITIES</b>		
	(a) Other Current Liabilities	464	486
	(b) Short Term Provisions	1,805	1,805
	<b>Sub Total - Current Liabilities</b>	<b>2,269</b>	<b>2,291</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>53,676</b>	<b>51,993</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>NON CURRENT ASSETS</b>		
	(a) <b>FIXED ASSETS</b>	113	131
	(b) Non Current Investment	+	
		16,844	16,844
	<b>Sub Total - Non - Current Assets</b>	<b>16,957</b>	<b>16,975</b>
<b>2</b>	<b>CURRENT ASSETS</b>		
	(a) Cash & Cash Equivalents	1,524	1,747
	(b) Short Term Loans and Advances	16,005	15,005
	(b) Long Term Loans and Advances	19,190	18,266
	<b>Sub Total - Current Assets</b>	<b>36,719</b>	<b>35,018</b>
	<b>TOTAL ASSETS</b>	<b>53,676</b>	<b>51,993</b>

By Order of the Board  
For Chemo - Pharma Laboratories Limited



*Ashok Somani*  
**ASHOK SOMANI**  
**DIRECTOR**

Place : Mumbai  
Date : 21st October, 2014